Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke

This is an interventional treatment trial for Right Hemisphere Stroke focused on measuring Stroke, Hemispatial neglect, Unilateral neglect, Spatial neglect, Motor, Weakness Read More

Inclusion Criteria:

• Confirmed clinical diagnosis of right-hemisphere stroke.
• Able to give informed consent.
• Presence of left hemispatial neglect defined by a deficit in finding leftward targets on standard cancellation or visual search tests68-70. (A deficit on the line bisection test alone will not be sufficient for inclusion, as a previous study shows that there is no significant relationship between performance on this test and spatial working memory capacity37).
• Presence of motor deficits: all patients will have suffered from first-ever clinically defined stroke resulting in weakness of at least wrist and finger extensors, and hand interossei (to </= 4+ on the Medical Research Council scale), at the time of recruitment.
• Age over 18 years.
• More than 9 days since stroke-onset (Note that on our protocol patches do not commence until a minimum of 6 days after the study begins. Thus patients will not receive drug / placebo until a minimum of 15 days post-stroke).
• Able and willing to use patches of drug/placebo and assessments at regular intervals as defined by the protocol.
• Able to comply with study requirements.
• If female and of child-bearing potential, subject has a negative serum pregnancy test within two days of enrollment.

Exclusion Criteria:

• Pre-existing neurological conditions that would confound cognitive and motor assessments, e.g. dementia, Parkinson's disease, Multiple Sclerosis.
• Presence of acute concomitant illness, e.g. infection, unstable angina, myocardial infarction or heart, respiratory, renal or liver failure which, based on clinical judgment, would be considered to confound interpretation of results.
• Systolic blood pressure less than 120 mmHg and / or diastolic less than 70 mmHg.
• Exposure to any other investigational drug within 30 days of enrollment in the study.
• History (obtained from patient and medical records) of clinically significant drug or alcohol abuse within 6 months prior to enrollment into the study.
• Pregnancy (because the effects of rotigotine on the fetus and mother in pregnancy are not known). If female and of child-bearing potential, a serum pregnancy test will be performed within two days of enrollment.
• Mothers who are breast feeding (because the effects of rotigotine on the newborn have not been established)